Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Torsemide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 21 USDMF, 19 CEP/COS, 1 JDMF, 8 EU WC, 3 KDMF, 13 NDC API, 30 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

12 Intermediate Suppliers

12 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

215 FDF Dossiers, 48 FDA Orange Book, 122 Europe, 5 Canada, 14 South Africa, 26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 1 DKSH, 4 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 1 BioSpectra, 1 Clariant, 6 DFE Pharma, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 25 Kerry, 12 Microlex e.U, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 15 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 10 Sigachi Industries, 2 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders, 28 Disintegrants & Superdisintegrants, 26 Direct Compression, 20 Granulation, 16 Thickeners and Stabilizers, 13 Co-Processed Excipients, 12 Lubricants & Glidants, 9 Solubilizers, 8 Chewable & Orodispersible Aids, 7 Controlled & Modified Release, 6 Parenteral, 5 Taste Masking, 5 Coating Systems & Additives, 3 Topical, 3 Emulsifying Agents, 3 Film Formers & Plasticizers, 2 API Stability Enhancers, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 5 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 103 Regulatory FDF Prices

MARKET PLACE

12 APIs, 12 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

2 US Patents, 5 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 5 USP, 14 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
24/02/2025	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD	15738	TORSEMIDE	2001-11-26	Active	II	N/A
24/02/2025	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD	15222	TORSEMIDE	2001-01-03	Inactive	II	N/A

Torsemide

Torsemide

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

21 USDMF

19 CEP/COS

1 JDMF

8 EU WC

3 KDMF

13 NDC API

30 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

12 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

215 FDF Dossiers

48 FDA Orange Book

122 Europe

5 Canada

14 South Africa

26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

1 DKSH

4 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

4 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

14 BASF

1 BioSpectra

1 Clariant

6 DFE Pharma

6 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

25 Kerry

12 Microlex e.U

2 Novo Excipients

4 Pharmatrans-Sanaq

4 Pluviaendo

3 Prachin Chemical

15 Roquette

1 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

10 Sigachi Industries

2 Ulanqab Kema New Material

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders

28 Disintegrants & Superdisintegrants

26 Direct Compression

20 Granulation

16 Thickeners and Stabilizers

13 Co-Processed Excipients

12 Lubricants & Glidants

9 Solubilizers

8 Chewable & Orodispersible Aids

7 Controlled & Modified Release

6 Parenteral

5 Taste Masking

5 Coating Systems & Additives

3 Topical

3 Emulsifying Agents

3 Film Formers & Plasticizers

2 API Stability Enhancers

TABLET;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons